Literature DB >> 12381305

Structural and immunological characterisation of heteroclitic peptide analogues corresponding to the 600-612 region of the HIV envelope gp41 glycoprotein.

Angélique Phan Chan Du1, David Limal, Vincent Semetey, Hayet Dali, Michel Jolivet, Claude Desgranges, Manh Thông Cung, Jean-Paul Briand, Marie-Christine Petit, Sylviane Muller.   

Abstract

The conformational and immunological properties of different analogues corresponding to the 600-612 disulfide loop of the human immunodeficiency virus (HIV) gp41 glycoprotein envelope were studied. Fourteen analogues were designed and synthesised; namely, a series of seven analogues in which the disulfide bond was replaced by a lactam bridge and a series of seven analogues in which one residue of each analogue at a time, was replaced by its corresponding homologised alpha-amino acid (beta(3)-amino acid). In the case of the lactam analogues, the influence of the two possible CO-NH and NH-CO orientations of the lactam bridge as well as the size of the lactam ring was explored. The analogues were tested in ELISA with monoclonal antibodies raised against the 600-612 cyclic parent peptide as well as with sera from HIV-1 infected patients. A structural analysis of the parent and analogue peptides was carried out in dimethyl sulfoxide (DMSO-d(6)) using two-dimensional NMR techniques and molecular dynamics simulations. Comparison of the own conformation of the cyclic analogues with their either strong or weak reactivity with the antibodies reveals structural features that may be correlated with the antibody reactivity. Thus, a close structural similarity, particularly a characteristic orientation of the side-chains of residues Lys606, Leu607 and Ile608 in the loop, was found in certain beta(3)-analogues that were better recognised than the parent peptide by anti-peptide mouse monoclonal antibodies and patients' antibodies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12381305     DOI: 10.1016/s0022-2836(02)00701-5

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  7 in total

1.  Epitope reactions can be gauged by relative antibody discriminating specificity (RADS) values supported by deletion, substitution and cysteine bridge formation analyses: potential uses in pathogenesis studies.

Authors:  Andrew K I Falconar
Journal:  BMC Res Notes       Date:  2012-07-05

2.  A cocktail of thermally stable, chemically synthesized capture agents for the efficient detection of anti-gp41 antibodies from human sera.

Authors:  Jessica A Pfeilsticker; Aiko Umeda; Blake Farrow; Connie L Hsueh; Kaycie M Deyle; Jocelyn T Kim; Bert T Lai; James R Heath
Journal:  PLoS One       Date:  2013-10-07       Impact factor: 3.240

3.  Molecular basis for epitope recognition by non-neutralizing anti-gp41 antibody F240.

Authors:  Neelakshi Gohain; William D Tolbert; Chiara Orlandi; Jonathan Richard; Shilei Ding; Xishan Chen; Daniel A Bonsor; Eric J Sundberg; Wuyuan Lu; Krishanu Ray; Andrés Finzi; George K Lewis; Marzena Pazgier
Journal:  Sci Rep       Date:  2016-11-09       Impact factor: 4.379

4.  Conformational plasticity of the HIV-1 gp41 immunodominant region is recognized by multiple non-neutralizing antibodies.

Authors:  Jonathan D Cook; Adree Khondker; Jeffrey E Lee
Journal:  Commun Biol       Date:  2022-03-31

5.  Forced virus evolution reveals functional crosstalk between the disulfide bonded region and membrane proximal ectodomain region of HIV-1 gp41.

Authors:  Ashraf I Khasawneh; Annemarie Laumaea; David N Harrison; Anna K Bellamy-McIntyre; Heidi E Drummer; Pantelis Poumbourios
Journal:  Retrovirology       Date:  2013-04-23       Impact factor: 4.602

6.  Computer-Aided Approaches for Targeting HIVgp41.

Authors:  William J Allen; Robert C Rizzo
Journal:  Biology (Basel)       Date:  2012-08-20

7.  Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques.

Authors:  Sampa Santra; Georgia D Tomaras; Ranjit Warrier; Nathan I Nicely; Hua-Xin Liao; Justin Pollara; Pinghuang Liu; S Munir Alam; Ruijun Zhang; Sarah L Cocklin; Xiaoying Shen; Ryan Duffy; Shi-Mao Xia; Robert J Schutte; Charles W Pemble Iv; S Moses Dennison; Hui Li; Andrew Chao; Kora Vidnovic; Abbey Evans; Katja Klein; Amit Kumar; James Robinson; Gary Landucci; Donald N Forthal; David C Montefiori; Jaranit Kaewkungwal; Sorachai Nitayaphan; Punnee Pitisuttithum; Supachai Rerks-Ngarm; Merlin L Robb; Nelson L Michael; Jerome H Kim; Kelly A Soderberg; Elena E Giorgi; Lily Blair; Bette T Korber; Christiane Moog; Robin J Shattock; Norman L Letvin; Joern E Schmitz; M A Moody; Feng Gao; Guido Ferrari; George M Shaw; Barton F Haynes
Journal:  PLoS Pathog       Date:  2015-08-03       Impact factor: 6.823

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.